iiinova — where your digital self keeps evolving

JAMA Oncology @jamaoncology.com · 08/10/2026

Among patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and durable disease control, with no muscle-invasive or metastatic progression during follow-up. ja.ma/479i4jj

Four charts titled 'DOR and Survival Outcomes.' A shows DOR for high-risk disease. B details time to complete response & duration for patients (legend for ongoing, recurrence, death). C and D show progression-free and overall survival, respectively. All Kaplan-Meier curves start high, plateauing above 0.8 over 40-50 months.

000

JAMA Oncology @jamaoncology.com · 25/09/2026

Among patients with nonmetastatic #HeadNeckCancer receiving radiation therapy, financial toxicity was associated with worse quality of life and substantial out-of-pocket expenses. ja.ma/4dzMI8Z

001

JAMA Oncology @jamaoncology.com · 25/09/2026

This review examines ovarian metastases from colorectral cancer and the potential role of surgical resection of metastatic disease. ja.ma/4iKDA4S

000

JAMA Oncology @jamaoncology.com · 25/09/2026

Among adults in China and the UK, modifiable lifestyle factors and health conditions accounted for most of the male-female #Cancer incidence gap in China but only a smaller fraction in the UK. ja.ma/4ygALxm

000

JAMA Oncology @jamaoncology.com · 18/09/2026

Prebiopsy #MRI use before #ProstateCancer biopsy increased in the US from 2017 to 2026, reaching 64.1% of biopsy-naive patients, but uptake remained incomplete. ja.ma/4gPW16U

Two line graphs show prebiopsy MRI use. Graph A (2017-2026) shows an increasing trend for 'biopsy naive' and 'prior negative biopsy result' patients, with the latter consistently higher. Graph B (2024-2026) details these percentages across RUCA, Race, Age, & PSA subgroups.

000

JAMA Oncology @jamaoncology.com · 18/09/2026

Editorial: In HPV 16–positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus pembrolizumab demonstrated activity in immune checkpoint inhibitor–naive disease but not after prior immune checkpoint inhibitor exposure. ja.ma/4xW1IWP

JAMA Oncology editorial titled "Is Antigen-Specific Immunotherapy a New Frontier in HPV-Initiated Head and Neck Cancer?" by Kyunghee Burkitt, DO, PhD, and Barbara A. Burtness, MD. Published online September 17, 2026. DOI: 10.1001/jamaoncol.2026.3459.

000

JAMA Oncology @jamaoncology.com · 17/09/2026

Meta-analysis: In #HeadAndNeckCancer with programmed cell death 1 ligand 1 combined positive score <1, #ImmuneCheckpointInhibitors were likely associated with reduced survival, including significantly reduced overall survival in recurrent or metastatic disease. ja.ma/46uMnAC

Figure 2: Meta-analyses of ICIs in head and neck squamous cell carcinoma (PD-L1 CPS < 1) by disease setting. A) Recurrent/metastatic: Forest plot shows pooled HRs (Bayesian 1.42, Frequentist 1.46) favor control (P<.001). B) Locally advanced: Pooled HRs (Bayesian 1.19, Frequentist 1.18) also favor control but are not significant (P=.41).

000

JAMA Oncology @jamaoncology.com · 17/09/2026

In #HPV16-positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus #Pembrolizumab showed antitumor activity and manageable safety in immune checkpoint inhibitor–naive patients, but no objective responses in resistant patients. ja.ma/4xVtvql

$Kaplan-Meier curve shows overall survival in immune checkpoint inhibitor-naive population. Y-axis: Survival fraction (0-1.0). X-axis: Time (mo, 0-48). Curve declines from 1.0 to ~0.43. Key survival: 9-mo (84.7%), 12-mo (78.5%), 24-mo (67.6%). No. at risk decreases from 53 to 0.$

000

JAMA Oncology @jamaoncology.com · 07/09/2026

Among patients with #ERBB2-positive #BreastCancer, neoadjuvant anbenitamab plus HB1801 was associated with a higher total pathologic complete response rate vs trastuzumab, pertuzumab, and docetaxel, with similar grade 3 or 4 toxic effects. ja.ma/46FBax8

JAMA Oncology: RCT of Anbenitamab+HB1801 for ERBB2-positive breast cancer. 521 female patients (median age 52) in 61 Chinese hospitals. Anbenitamab+HB1801 (62.4% tpCR) outperformed THP (51.2% tpCR), with an 11.4% absolute difference (P=.004).

000

JAMA Oncology @jamaoncology.com · 06/09/2026

In #CancerCare, biosimilar entry for bevacizumab, rituximab, and trastuzumab was associated with lower reference product prices and market share, along with lower payer and patient costs. ja.ma/4ig46mA

000

JAMA Oncology @jamaoncology.com · 06/09/2026

#ColorectalCancer mortality declined nationally among US adults aged ≥45 years from 2000 to 2019, but county-level disparities persisted, with some counties exceeding 100 deaths per 100 000 among American Indian or Alaska Native and Black populations. ja.ma/4ymxIDm

Four line graphs display age-standardized colorectal cancer mortality rates (deaths per 100,000) from 2000-2020 by race/ethnicity for males/females age ≥45 and <44. For ≥45, rates decline for all, with Black individuals highest. For <44, rates are lower & stable/slightly increasing.

010

JAMA Oncology @jamaoncology.com · 06/09/2026

In US #Cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions. ja.ma/3TbzUyG

Bar chart: Proportion of total within sponsor (%) by study purpose. Compares Federal (grey) & Industry (orange) sponsorship (0-6% scale). Federal is notably higher for Diagnostic, Health services, Prevention (highest at ~4.7%), Screening, & Supportive care. Industry is slightly higher for Basic Science & Device Feasibility. Each category includes OR, CI, P-values.

021

JAMA Oncology @jamaoncology.com · 06/09/2026

In Denmark, #Meningioma incidence increased from 2010 to 2023, but #Surgery and #Radiotherapy rates remained stable, indicating that more diagnoses did not lead to more treatment. ja.ma/465TUFZ

Two graphs on meningioma incidence by sex (2010-2023). Top bar chart shows female patients (orange) consistently outnumber males (grey), with overall numbers rising. Bottom line chart shows age-standardized incidence; females (orange line) have higher rates than total (blue) and males (dark grey), all trending up.

000

JAMA Oncology @jamaoncology.com · 14/08/2026

A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis? ja.ma/4wVRi9f

JAMA Clinical Challenge: Oral Ulcers in MDS. A: Large tongue ulcer with fibrinous base. B: Microscopic view of a skin biopsy showing intense dermal inflammation with inflammatory cells (black arrowheads) & leukocytoclasia (yellow arrowheads). Clinical case with diagnosis options.

000

JAMA Oncology @jamaoncology.com · 13/08/2026

Among patients with early #TripleNegativeBreastCancer, tissue-free #ctDNA detection during molecular residual disease surveillance was strongly prognostic for recurrence and supported testing when tumor tissue was unavailable. ja.ma/3S5A0Hu

Kaplan-Meier curve for ctDNA detection in triple negative breast cancer. Two lines show recurrence-free survival over time: 'ctDNA not detected' (blue, high survival) and 'ctDNA detected' (orange, sharply decreased survival). HR 27.2; P < .001. Table shows numbers at risk.

000

JAMA Oncology @jamaoncology.com · 13/08/2026

Among men with #ProstateCancer starting concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor, #MetabolicSyndrome and related abnormalities were frequently documented early, with hypertension the most common outcome. ja.ma/3TW65Cf

Survival Curves: Cumulative incidence of metabolic syndrome after ADT/ARPI therapy by age group. Y-axis: Cumulative incidence (0-0.5). X-axis: Days (0-360). 70-79y group shows highest incidence, rising to over 0.4. Other groups (<70y, ≥80y) have lower, similar rates. Table of "No. at risk" included.

010

JAMA Oncology @jamaoncology.com · 12/08/2026

Among patients with metastatic #BreastCancer, alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference. ja.ma/4xzjmPF

JAMA Oncology RCT: Electronic monitoring with alerts for 909 women with metastatic breast cancer reduced fatigue. A graph shows the intervention group's mean fatigue score dropping below the control group's higher score over 12 months.

000

JAMA Oncology @jamaoncology.com · 12/08/2026

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. ja.ma/3UsSpyJ

JAMA Oncology RCT for ES-SCLC. Study on 68 patients (25F, 43M) comparing Atezolizumab+TRT versus Atezolizumab only. Lungs icon & biohazard symbol. Atezolizumab only arm showed higher overall survival (13.4 vs 6.7 months). Combo arm recruitment terminated early due to adverse events. Survival curve graph shows divergent trends.

000

JAMA Oncology @jamaoncology.com · 10/08/2026

010

JAMA Oncology @jamaoncology.com · 09/08/2026

In patients with #ProstateCancer receiving #AdaptiveTherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#PSA) dynamics predicted time to progression and overall survival better than standard PSA metrics. ja.ma/4wbDsyf

Scatter plots validating mathematical biomarkers. 3 graphs show expected vs. simulated outcomes for adaptive therapy score, mean daily dose, and TTP. Points strongly correlate to a dashed diagonal line. Plot C has patient identifiers by color.

010

JAMA Oncology @jamaoncology.com · 09/08/2026

000

JAMA Oncology @jamaoncology.com · 08/08/2026

010

JAMA Oncology @jamaoncology.com · 08/08/2026

000

JAMA Oncology @jamaoncology.com · 27/07/2026

000

JAMA Oncology @jamaoncology.com · 27/07/2026

💬 Viewpoint: In #Oncology, payment incentives may shape the context of care recommendations, and directional disclosure of those incentives deserves consideration as part of informed consent. ja.ma/4x8ET1B

JAMA Oncology article titled "Viewpoint: Why Incentive Transparency Matters for Informed Consent" by Adam C. Powell, Daniel A. Goldstein, and Bryan A. Loy. Published Online: July 23, 2026.

020

JAMA Oncology @jamaoncology.com · 27/07/2026

In a phase 1 trial of ultralow-dose IL-10–expressing CD19 CAR T cells for diffuse large B-cell lymphoma, 92% of adults had objective responses and most toxicities were grade 1-2, supporting further evaluation of cytokine-engineered CAR T strategies. ja.ma/4fk0oGA

Figure 2. Clinical Response to Interleukin 10-Expressing CD19 Chimeric Antigen Receptor T Cells. This bar chart shows individual patient responses over time (0-30 months) using stacked bars for disease status (Active, CR, PR, PD types) and symbols for retreatment, follow-up, or death.

010

JAMA Oncology @jamaoncology.com · 25/07/2026

Among adults with #obesity, use of #GLP-1 receptor agonists was associated with reduced risk of endometrial, ovarian, and meningioma cancers and a slight increase in kidney #cancer risk. 📖 Read the full article for more details: ja.ma/4hdC2Q4

020

JAMA Oncology @jamaoncology.com · 17/07/2026

In metastatic breast cancer trials, progression-free survival by blinded central review and investigator assessment was similar, supporting use of either method for endpoint evaluation. ja.ma/4w2Lcn4

JAMA Oncology article: 'Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review. A Systematic Review and Meta-Analysis.' Authors: Lis V. Ravani, Z. Bagheri, et al.

000

JAMA Oncology @jamaoncology.com · 11/07/2026

JAMA Oncology study: Atezolizumab maintenance for ES-SCLC. 68 patients randomized. Kaplan-Meier plot shows Atezolizumab only arm (median OS 13.4 mo) had better survival than Atezolizumab+TRT arm (6.7 mo). Recruitment ended due to adverse events in TRT arm.

020

JAMA Oncology @jamaoncology.com · 10/07/2026

Among patients with advanced #BiliaryTractCancer, durvalumab plus gemcitabine and cisplatin provided sustained 4-year overall survival benefit and a comparable safety profile vs placebo plus chemotherapy ja.ma/4ygxazN

RCT: Durvalumab + Chemo for advanced biliary tract cancer. 685 participants (median age 64) were randomized. Findings show Durvalumab + GemCis (341) significantly improved OS vs. Placebo + GemCis (344). HR 0.75. Graph shows survival curves.

011

JAMA Oncology @jamaoncology.com · 01/07/2026

Genomic profiling of consecutive meningiomas found associations between copy number alterations, somatic variants, tumor grade, and patient characteristics, offering insights into prognosis and therapeutic vulnerability. ja.ma/3SGkCRU

JAMA Oncology article titled "Prospective Genomic Profiling of Consecutive Meningiomas" by Minh P. Nguyen, Kanish Mirchia, Brooke C. Braman, et al. Published online April 9, 2026. Includes navigation, author affiliations, article info, and share icons.

010

JAMA Oncology @jamaoncology.com · 25/06/2026

Patients with platinum-sensitive recurrent #OvarianCancer and exceptional response to PARP inhibitors showed ≥78% ten-year progression-free survival, with low risk of myeloid cancers, regardless of maintenance duration. ja.ma/44AA3h3

Figure 2. Bar graphs display outcomes for 5 patients after starting PARP inhibitors. Timelines mark events like PARP discontinuation, MDS/AML diagnosis, & death over several years. Most patients experienced an event, often within 5-10 years post-treatment.

010

JAMA Oncology @jamaoncology.com · 22/06/2026

The 9-valent #HPV vaccine was linked to reduced risk of #HPVRelatedCancers in males aged 9 to 26 years, with consistent protection in both the adolescent and young adult groups. ja.ma/4uPlDod

Cumulative incidence graph over 9 years. Y-axis: Cumulative incidence per 100,000 persons (0-60). X-axis: Years after index event (0-9). The 'Unvaccinated' line (orange) consistently shows a higher incidence, rising to nearly 50. The 'Vaccinated' line (dark) shows a lower incidence, rising to almost 40.

000

JAMA Oncology @jamaoncology.com · 21/06/2026

Pretreatment MRI findings including extraprostatic extension and seminal vesicle invasion were independently prognostic for recurrence, metastasis, and mortality after radical prostatectomy. #ProstateCancer ja.ma/4xGq5Ii

Stacked bar chart: Risk of bias. Most categories (participation, attrition, prognostic factor measurement, outcome measurement, statistical analysis) are nearly all low risk. Confounding shows ~30% low, ~65% moderate, ~5% high risk. Overall: ~90% low, ~10% moderate. Legend: Low, Moderate, High risk of bias.

010

JAMA Oncology @jamaoncology.com · 20/06/2026

Clonal hematopoiesis of indeterminate potential (CHIP) was associated with higher risk of trastuzumab-related cardiotoxicity and heart failure in patients with #BreastCancer. ja.ma/446aHaZ

Bar graphs illustrating Tumor-Infiltrating Clonal Hematopoiesis (TI-CH) prevalence across CHIP driver genes & tumor types. TET2 is the most common CHIP driver variant. TI-CH-negative disease predominates over TI-CH-positive. Colon & rectum show the highest TI-CH variant distribution.

000

JAMA Oncology @jamaoncology.com · 19/06/2026

Among adults with lymphoma or myeloma, second primary malignant neoplasms after T-cell–engaging bispecific antibody therapy occurred in 3.5%, with most second primary malignant neoplasms being skin or hematologic cancers. ja.ma/3SlsYOG

Figure 2. Distribution of SPM Entities, a horizontal bar chart showing Total SPMs by Cancer type (y-axis) vs. SPM events (x-axis, 0-14). Nonmelanoma skin cancer has the highest SPM events (approx. 9), followed by MDS and Unknown (approx. 4 each).

011

JAMA Oncology @jamaoncology.com · 19/06/2026

A single-fraction 19 Gy SBRT regimen for localized #ProstateCancer achieved 92.9% 3-year biochemical relapse-free survival, with grade 2 genitourinary and gastrointestinal adverse event rates below 10% and 5%, respectively, at 3 years. ja.ma/4wjqpeX

Figure 4. Bar graph showing percentage changes from baseline across Urinary, Bowel, Hormonal, Sexual, and Overall satisfaction domains of the Expanded Prostate Cancer Index Composite. Changes are classified as No, Little, Moderate, or Substantial. Most domains show high 'No change' percentages.

010

JAMA Oncology @jamaoncology.com · 16/06/2026

Sequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy. ja.ma/4eOqlwD

$Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing "with" vs. "without chemotherapy" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.$

000

JAMA Oncology @jamaoncology.com · 13/06/2026

A 58-year-old woman with #BreastCancer with multiple prior courses of systemic treatments presented with hypotension, hypoxia, significant polyuria, and polydipsia. Mild thickening of the pituitary stalk was seen. ✍️ What is your diagnosis? ja.ma/4vAqpXs

Sagittal (A) and coronal (B) MRI brain scans show thickening of the pituitary stalk (arrowheads, 3.92mm). This image is from a JAMA Oncology article: 'Hypernatremia and Polyuria in a Patient With Metastatic Breast Cancer,' which also includes a 'What is your diagnosis?' section.

010

JAMA Oncology @jamaoncology.com · 12/06/2026

This Special Communication provides consensus recommendations on the acquisition, interpretation, and reporting of prostate magnetic resonance imaging for cancer screening. ja.ma/4eApoJc

Schematic of Stage-Gated MRI interpretation shows two stages. Top row (positive findings): T2WI, DWI (high b), DWI (ADC map), and T2WI (sagittal plane) scans, all with pink arrows pointing to lesions. Bottom row (negative findings): T2WI & DWI (high b) scans, leading to 'Not reviewed'.

000

JAMA Oncology @jamaoncology.com · 11/06/2026

Avelumab combined with methotrexate resulted in >95% durable remission and preserved #fertility in low-risk gestational trophoblastic #tumors, with a manageable safety profile. ja.ma/3RRcFcp

Protocol for low-risk gestational trophoblastic tumors (FIGO score ≤6): Curative treatment with 8-day Methotrexate and Avelumab until hCG normalization. Followed by 3 consolidation cycles of each drug, then a 3-year hCG monitoring follow-up: weekly, bi-weekly, monthly, then quarterly.

010

JAMA Oncology @jamaoncology.com · 09/06/2026

000

JAMA Oncology @jamaoncology.com · 06/06/2026

Among patients with early age–onset #ColorectalCancer in Texas, treatment delays longer than six weeks were associated with reduced survival, and language barriers represented a major risk factor contributing to delayed initiation of definitive therapy. ja.ma/3S1igN7

Kaplan-Meier survival curves show overall survival for EOCRC patients with/without treatment delay across 4 graphs: general, localized, regional, metastatic. Treatment delay consistently leads to lower survival (P<.001-.047) over 72 months. Y-axis: Overall survival %.

031

JAMA Oncology @jamaoncology.com · 06/06/2026

000

JAMA Oncology @jamaoncology.com · 05/06/2026

A phase 3 trial shows serplulimab plus chemotherapy improved overall survival and 4-year survival rates vs chemotherapy alone in extensive-stage small cell #LungCancer, with durable benefit and manageable safety. ja.ma/4x4hcrO

Two Kaplan-Meier curves. Top: Overall survival, showing Serplulimab+chemotherapy (orange) above Placebo+chemotherapy (teal) [HR 0.60, P<.001]. Bottom: Progression-free survival, with Serplulimab+chemotherapy clearly outperforming Placebo+chemotherapy [HR 0.47, P<.001].

010

JAMA Oncology @jamaoncology.com · 05/06/2026

Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #Dermatitis, with no serious treatment-related adverse events. ja.ma/4vAMjdf

JAMA Oncology Research Letter: "Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial." Authors: Chengshui Chen, Xinyu Liang, Zheng Peng et al. Published Online: March 5, 2026. doi:10.1001/jamaoncol.2026.0136.

010

JAMA Oncology @jamaoncology.com · 04/06/2026

A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #NSCLC with high #PDL1, though with greater toxicity. ja.ma/43Nj4aU

Kaplan-Meier curves compare Chemoimmunotherapy (orange) vs PD-(L)1 inhibitor monotherapy (blue) for overall (A) and progression-free (B) survival. Chemoimmunotherapy shows higher survival probabilities in both graphs. HR values are 0.74 (A) and 0.67 (B), P<.001 for both.

021

JAMA Oncology @jamaoncology.com · 01/06/2026

From @jama.com: In resected non-small cell lung #cancer, adjuvant #nivolumab following standard care was not associated with improved survival or recurrence risk compared with observation, even in tumors with high PD-L1 expression. #ASCO26 @ascocancer.bsky.social ja.ma/3RypEQ2

JAMA study: Adjuvant nivolumab was not associated with improved disease-free survival in resected NSCLC patients without EGFR and ALK alterations. 935 patients randomized (466 nivolumab, 469 observation). Median disease-free survival: Nivolumab 71.3 mos (overall), Observation 68.8 mos (overall).

010

JAMA Oncology @jamaoncology.com · 01/06/2026

A phase 3 trial demonstrated that fovinaciclib plus aromatase inhibitor showed significant and clinically improved progression-free survival with manageable safety in hormone receptor-positive, ERBB2-negative advanced #BreastCancer. #ASCO26 @ascocancer.bsky.social ja.ma/3QdaXRV

RCT: Fovinaciclib for Advanced Breast Cancer. A trial with 417 women randomized Fovinaciclib vs. placebo. Fovinaciclib significantly improved progression-free survival (PFS) compared to placebo, shown by a Kaplan-Meier graph (HR 0.55, 95% CI 0.38-0.77).

000

JAMA Oncology @jamaoncology.com · 31/05/2026

Among women with breast cancer gene pathogenic variants (PV), most would not have received high-risk screening based on clinical or polygenic risk, supporting the need for germline PV testing in risk-based #BreastCancer screening. #ASCO26 @ascocancer.bsky.social ja.ma/4dVLSD6

Sankey plots from the WISDOM Study show breast screening assignments by age group. Panel A (40-49 y) & B (50-74 y) illustrate the flow from BCSC model to BCSC-PRS model to Actual assignment. Node colors represent high-risk, annual, biennial mammography, and no/stop screening.

010